Natixis’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Natixis’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-41,737	Closed	-$13.2M	–	1272
2023 Q4	$13.2M	Buy	+41,737	New	+$8.11M	0.1%	179
2022 Q4	–	Sell	-5,000	Closed	-$1.13M	–	1393
2022 Q3	$1.13M	Hold	5,000	–	–	0.01%	738
2022 Q2	$633K	Sell	5,000 -85,142	-94%	-$9.79M	﹤0.01%	903
2022 Q1	$11.4M	Buy	90,142 +57,010	+172%	+$6.42M	0.04%	390
2021 Q4	$4.34M	Buy	+33,132	New	+$4.28M	0.01%	585

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Natixis's KRTX Position: Q1 2024 in Review

Natixis sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 41,737 shares — an estimated $13.2M sold.

Natixis first reported a position in KRTX in Q4 2021 and held it in 5 quarters. The position peaked at $13.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Natixis reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Natixis sold 41,737 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $13.2M.
Natixis first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2021 and held it in 5 quarters.
Natixis's Karuna Therapeutics, Inc. Common Stock position peaked at $13.2M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Natixis's 13F filing for Q1 2024, filed 13 May 2024.